Market Newsdesk

• Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024
• RUCONEST® third quarter revenu
  e
  increased
  by
  29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribers
• Joenja® (leniolisib) third quarter reven
  ue
  increased
  b
  y 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy
• FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years with APDS with decision expected by January 2026
• Third quarter operating profit increased by 285% to US$15.8 million, compared to US$4.1 million in the third quarter 2024
• Generated US$32.0 million in cash flow from operations during the quarter and US$44.0 million year to date
• 2025 total revenue guidance raised to US$365 – US$375 million, up from prior US$335 – US$350 million
• Leverne Marsh appointed Chief Commercial Officer, effective January 1, 2026; Stephen Toor to step down as CCO at year-end and remain an advisor to the company
• Pharming to host a conference call today at 13:30 CET (7:30 am ET)

Leiden, the Netherlands, November 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the three months ended September 30, 2025.

Chief Executive Officer, Fabrice Chouraqui, commented:

“We delivered another strong quarter, with significant growth in revenue and profitability, reinforcing our confidence in the business.

We continue to drive the performance of RUCONEST® in the competitive U.S. HAE market, fueled by new patient enrollments and an expanding prescriber base, even amid the launch of a new oral on-demand therapy in July. Joenja® also delivered significant revenue growth, driven by a 25% year-over-year increase in patients on paid therapy and consistently high adherence rates. Looking ahead, we expect continued uptake amongst APDS patients aged 12 and older and new sources of growth including the anticipated pediatric label expansion for patients aged 4 to 11, the reclassification of variants of uncertain significance, or VUSs, and regulatory approvals enabling launches in several major markets.

Our pipeline is advancing well, unlocking potential new indications for leniolisib in broader primary immunodeficiency populations and addressing significant unmet needs in primary mitochondrial disease with KL1333.

To capitalize on these growth catalysts and pipeline opportunities, we recently announced a significant reduction in general and administrative headcount to optimize capital deployment to high growth initiatives. This disciplined approach combined with strong operating results — US$32 million in third-quarter operating cash flow — reinforces our ability to accelerate Pharming’s development and create value for our stakeholders and shareholders.

Based on this strong performance and our outlook for the final quarter of the year, we are raising our full-year revenue guidance.

I am pleased to welcome Leverne Marsh as Chief Commercial Officer, effective January 1, 2026, succeeding Stephen Toor. Leverne brings a strong track record of high impact launches and deep experience across the commercial spectrum, which will be instrumental as we continue executing our strategy to become a leading global rare disease company. I would like to thank Steve for his contributions to Pharming over the past nine years and for his legacy in building a uniquely patient-focused culture.

I want to thank our teams for their dedication and resilience in driving our mission forward.”

Third quarter highlights

Commercialized assets

RUCONEST® marketed for the treatment of acute HAE attacks

Strong RUCONEST® growth continued in the third quarter of 2025, with revenue of US$82.2 million, a 29% increase compared to the third quarter of 2024. Revenue for the first nine months of 2025 was US$231.2 million, a 34% increase compared to the same period in 2024.

In the U.S. market, we continued to grow the patient and prescriber base during the quarter, notwithstanding the market entry of a new oral on-demand HAE product in early July. Significant patient growth over the prior year was driven by patients who rely on RUCONEST® for its efficacy, reliability and rapid onset via IV administration. Unit sales volume in the U.S. increased by 24% in the third quarter and 28% in the first nine months.

Pharming has made the strategic decision to withdraw RUCONEST® from registration and/or commercialization in all non-US markets. These markets contributed only US$1.1 million, or 1.3% of total RUCONEST® revenue in the current quarter and have never demonstrated financial sustainability. Ensuring continuity of care and minimizing the impact on patients during this transition remain our highest priorities. This decision also enables Pharming to reallocate resources toward pipeline opportunities with greater long-term growth potential.

Joenja® (leniolisib) marketed for the treatment of APDS

Joenja® revenue increased to US$15.1 million in the third quarter of 2025, a 35% increase compared to the third quarter of 2024. Revenue for the first nine months of 2025 was US$38.4 million, a 20% increase compared to the same period in 2024. Unit sales volume increased by 34% in the third quarter of 2025, driven by a significant increase in patients on paid therapy in the U.S. and the U.K. launch in April 2025.

The U.S. market contributed 89% of third quarter revenue, while the EU and Rest of World (RoW) contributed 11%. The significant increase in EU and RoW revenue was primarily driven by strong patient uptake in the U.K.

As of September 30, 2025, we had 116 patients on paid therapy in the U.S., representing a 25% increase from the 93 patients at the end of the third quarter of 2024. The number of U.S. patients diagnosed with APDS that we have identified increased by 13 in the third quarter of 2025 and 36 year-to-date.

APDS patient finding

As of September 30, 2025, we have identified 990 diagnosed APDS patients of all ages globally, including 270 patients in the U.S. Of the identified patients in the U.S., 175 patients are 12 years of age or older and currently eligible for treatment with Joenja®, while 54 are between 4 and 11 years of age and would become eligible pending regulatory approval expected in January 2026.

VUS patient reclassification

There are currently over 1,400 known U.S. patients with a variant of uncertain significance, or VUS, in the PIK3CD and PIK3R1 genes implicated in APDS. We estimate that 20% of VUS patients could ultimately be diagnosed with APDS, thereby expanding the addressable patient population for Joenja®. Genetic testing laboratories are currently evaluating data from a study published in June 2025 in the leading peer-reviewed journal Cell, by researchers at Columbia University, to determine the process and potential to reclassify patients to APDS.

Joenja® (leniolisib) development

Leniolisib for APDS

As of September 30, 2025, there are 180 APDS patients in either a leniolisib Expanded Access Program (compassionate use), an ongoing clinical study, or a named patient program.

Pediatric label expansion

On July 31, 2025, we submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for leniolisib for the treatment of children aged 4 to 11 years diagnosed with APDS. On October 1, 2025, we announced that the FDA had accepted the sNDA and granted Priority Review of the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026. Assuming a positive decision, we plan a commercial launch for this pediatric age group in the first quarter of 2026.

The Phase III clinical trial evaluating a new pediatric formulation of leniolisib in children 1 to 6 years of age diagnosed with APDS completed enrollment in April 2025. We expect to report results from this study in the coming months and if the data are supportive we plan to seek regulatory approval for this younger pediatric population.

Organizational updates

On September 2, 2025, we announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025, strengthening our financial leadership as we continue to execute on our growth strategy. Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences industry.

On October 6, 2025, we announced the implementation of an organizational restructuring aligned with our previously announced plan to reduce general and administrative (G&A) expenses, to optimize capital deployment to our significant growth opportunities. The restructuring includes a 20% net reduction in non-commercial and non-medical headcount, primarily at our Netherlands headquarters. We remain on track to reduce total G&A expenses by 15% or US$10 million annually and anticipate one-time restructuring costs of approximately $7 million to be recorded in the fourth quarter of 2025 in connection with the headcount reduction.

We announce today that Ms. Leverne Marsh has been appointed Chief Commercial Officer (CCO), effective January 1, 2026, succeeding Stephen Toor, who will leave on December 31 and remain an advisor to the company. Ms. Marsh brings extensive experience across the commercial landscape, which will be instrumental as we continue executing our strategy to become a leading global rare disease company. At Novartis, she led major specialty care product launches and BD&L transactions in multiple franchise head roles in the US, ultimately serving as Chief Product Officer and Head of Strategy. Most recently, as Executive Vice President, Marketing for Dexcom, a leading medical technology company, Ms. Marsh drove accelerated growth in a fast-paced health tech environment and supported the expansion of the international footprint of the business. Her expertise in leveraging AI and analytics to advance commercial execution, will be a key asset as we advance our mission in rare diseases.

Corporate highlights

Pharming was promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025, reflecting our growing market capitalization and trading activity. The Euronext Amsterdam AMX index comprises 25 companies based on free-float market capitalization and liquidity.

We are working on options to mitigate the impact of recently announced U.S. tariffs. Although some uncertainties remain, such as potential tariff exclusions, we do not expect a material impact on our business or growth.

Financial Summary

Consolidated Statement of Income	3Q 2025	3Q 2024	9M 2025	9M 2024
Amounts in US$m except per share data
Total Revenues	97.3	74.8	269.6	204.5
Cost of sales	(7.1)	(6.8)	(24.4)	(23.2)
Gross profit	90.2	68.0	245.2	181.3
Other income	0.1	0.8	2.3	2.1
Research and development	(23.4)	(20.7)	(68.2)	(60.8)
General and administrative	(17.0)	(15.3)	(59.9)	(46.0)
Marketing and sales	(34.1)	(28.7)	(99.7)	(91.9)
Other Operating Costs	(74.5)	(64.7)	(227.9)	(198.7)
Operating profit (loss)	15.8	4.1	19.6	(15.3)
Finance income (expense) and share of net profits in associates	(3.1)	(2.6)	(11.6)	0.1
Profit (loss) before tax	12.7	1.5	8.0	(15.2)
Income tax credit (expense)	(5.2)	(2.5)	(10.8)	0.5
Profit (loss) for the period	7.5	(1.1)	(2.8)	(14.7)
Share Information
Basic, attributable to equity holders of the parent (US$)	0.011	(0.002)	(0.004)	(0.022)
Diluted, attributable to equity holders of the parent (US$)	0.010	(0.002)	(0.004)	(0.022)

Segment information – Revenues	3Q 2025	3Q 2024	9M 2025	9M 2024
Amounts in US$m
Revenue – RUCONEST® (US)	81.1	62.0	227.4	168.4
Revenue – RUCONEST® (EU and RoW)	1.1	1.6	3.9	4.2
Total Revenues – RUCONEST®	82.2	63.6	231.2	172.6
Revenue – Joenja® (US)	13.4	10.0	34.6	28.7
Revenue – Joenja® (EU and RoW)	1.7	1.2	3.7	3.2
Total Revenues – Joenja®	15.1	11.2	38.4	31.9
Total Revenues – US	94.5	72.0	262.0	197.1
Total Revenues – EU and RoW	2.7	2.8	7.6	7.4
Total Revenues	97.3	74.8	269.6	204.5

Consolidated Balance Sheet	September 30, 2025	December 31, 2024
Amounts in US$m
Cash and cash equivalents, restricted cash and marketable securities	168.9	169.4
Current assets	277.6	278.4
Total assets	473.8	400.0
Current liabilities	87.9	73.8
Equity	264.6	221.1

Underlying figures are unrounded. Therefore, totals may differ slightly from the sum of individual items due to rounding effects in the presentation of this press release.

Financial highlights

Third quarter 2025

For the third quarter of 2025, total revenues increased by US$22.4 million, or 30%, to US$97.3 million, compared to US$74.8 million in the third quarter of 2024. RUCONEST® revenues amounted to US$82.2 million, a 29% increase compared to the third quarter of 2024. This increase in RUCONEST® revenues was primarily driven by a volume increase in the U.S. Joenja® revenues amounted to US$15.1 million in the third quarter of 2025, a 34% increase compared to the third quarter of 2024. This increase in Joenja® revenues was primarily driven by an increase in volume.

Gross profit increased by US$22.2 million or 33% to US$90.2 million (3Q 2024: US$68.0 million), mainly due to the increase in revenues.

The operating profit increased 285% and amounted to US$15.8 million compared to US$4.1 million in the third quarter of 2024. Adjusted to exclude US$0.2 million of non-recurring Abliva acquisition-related expenses, the operating profit amounted to US$16.0 million. The improved operating result was primarily driven by an increase in revenues, partially offset by higher operating expenses.

The net finance result amounted to a loss of US$2.8 million compared to a loss of US$2.2 million in the third quarter of 2024. This was primarily driven by lower interest income due to a lower average overall cash position and decreased interest rates.

The Company had a net profit of US$7.5 million, compared to a net loss of US$1.0 million in the third quarter of 2024. The change was primarily driven by increased revenues, partially offset by higher operating expenses.

Cash generated from operations amounted to US$32.0 million, compared to US$9.7 million in the third quarter of 2024. Cash and cash equivalents, including restricted cash and marketable securities, increased from US$130.8 million at the end of the second quarter of 2025 to US$168.9 million at the end of the third quarter of 2025. This increase was primarily driven by the net cash flows generated from operating activities.

Nine months
2025

Total revenues increased 32% during the first nine months of 2025 to US$269.6 million, versus US$204.5 million during the first nine months of 2024. Total RUCONEST® revenues were 34% higher at US$231.2 million, compared to revenues of US$172.6 million for the first nine months of 2024. The increase in RUCONEST® revenues was primarily driven by an increase in volume. Joenja® revenues amounted to US$38.4 million in the first nine months of 2025, a 20% increase compared to the first nine months of 2024. This increase in Joenja® revenues was primarily driven by an increase in volume.

Gross profit increased by US$63.9 million or 35% to US$245.2 million (9M 2024: US$181.3 million), mainly due to the increase in revenues.

The operating profit amounted to US$19.6 million compared to an operating loss of US$15.3 million in the first nine months of 2024. Adjusted to exclude US$10.1 million of non-recurring Abliva acquisition-related expenses, of which US$8.0 million is included in General and administrative expenses and US$2.1 million is included in Research and development expenses, the operating profit amounted to US$29.7 million. The improved operating result was primarily driven by an increase in revenues, partially offset by higher operating expenses which include a total of US$20.4 million in Abliva-related expenses. Excluding these Abliva-related expenses, operating expenses increased by 4% compared to the first nine months of 2024.

The net finance result amounted to a loss of US$11.3 million compared to a gain of US$1.4 million in the first nine months of 2024. This decline was mainly driven by the absence of a one-time fair value gain recognized in the second quarter of 2024 following the reclassification of the convertible bond-related derivative to equity, as well as by unfavorable EUR/USD exchange rate movements in the nine months of 2025.

The Company had a net loss of US$2.8 million, compared to a net loss of US$14.7 million in the first nine months of 2024. The change was primarily driven by increased revenues, partially offset by a change in the net finance result and higher operating expenses, including US$10.1 million non-recurring Abliva acquisition-related expenses, most of which are not tax-deductible.

Cash generated from operations amounted to US$44.0 million, compared to US$11.1 million used in operations in the first nine months of 2024. Cash and cash equivalents, including restricted cash and marketable securities, decreased by US$0.5 million to US$168.9 million from US$169.4 million at the end of 2024, primarily driven by purchases of Abliva shares totaling US$68.0 million and non-recurring Abliva acquisition-related expenses totaling US$10.1 million, primarily offset by US$44.0 million of cash generated from operations.

Outlook/Summary

For 2025, the Company anticipates:

• Total revenues between US$365 million and US$375 million (23% to 26% growth).
• Total operating expenses between US$304 million and US$308 million, assuming constant currency, including US$10.2 million non-recurring Abliva-related transaction and integration expenses, but excluding one-time restructuring costs of approximately $7 million to be recorded in the fourth quarter of 2025.
• Continued growth of RUCONEST® in the acute HAE market.
• Significant growth in APDS patients on paid Joenja® (leniolisib) therapy in the U.S.
• Increasing ex-U.S. revenues for leniolisib, driven by funded access programs and commercial availability in the U.K.
• Progress towards additional regulatory approvals for leniolisib for APDS patients 12 years of age or older and for pediatric label expansion in key global markets.
• Advancing the two ongoing Phase II clinical trials in PIDs with immune dysregulation to significantly expand the long-term commercial potential of leniolisib.
• Advancing the ongoing pivotal FALCON clinical study for KL1333 in mitochondrial DNA-driven primary mitochondrial disease.
• Continued focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases.

No further specific financial guidance for 2025 is provided.

Additional information

Presentation
The conference call presentation is available on the Pharming.com website from 07:30 CET today.

Conference Call

The conference call will begin at 13:30 CET/07:30 ET on Thursday, November 6. A transcript will be made available on the Pharming.com website in the days following the call.

Please note, the Company will only take questions from dial-in attendees.

Webcast Link:

https://edge.media-server.com/mmc/p/vb724dzx

Conference call dial-in details:

https://register-conf.media-server.com/register/BI1b6a1a63294c427f91ab7b24a7c6484b

Additional information on how to register for the conference call/webcast can be found on the Pharming.com website.

For further public information, contact:

Investor Relations

Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: [email protected]

Media Relations

Global: Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
E: [email protected]

U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)
T: +1 (917) 882-9038

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

About Pharming Group N.V.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.

For more information, visit www.pharming.com and find us on LinkedIn.

Auditor’s involvement

The Condensed Consolidated Interim Financial Statements have not been audited by the Company’s statutory auditor.

Forward-looking Statements

This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as “aim”, “ambition”, ‘‘anticipate’’, ‘‘believe’’, ‘‘could’’, ‘‘estimate’’, ‘‘expect’’, ‘‘goals’’, ‘‘intend’’, ‘‘may’’, “milestones”, ‘‘objectives’’, ‘‘outlook’’, ‘‘plan’’, ‘‘probably’’, ‘‘project’’, ‘‘risks’’, “schedule”, ‘‘seek’’, ‘‘should’’, ‘‘target’’, ‘‘will’’ and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2024 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

Inside Information

This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Pharming Group N.V.

Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)

For the period ended September 30, 2025

• Condensed consolidated interim statement of income
• Condensed consolidated interim statement of comprehensive income
• Condensed consolidated interim balance sheet
• Condensed consolidated interim statement of changes in equity
• Condensed consolidated interim statement of cash flows

CONDENSED CONSOLIDATED INTERIM STATEMENT OF INCOME
For the period ended September 30
Amounts in US$ ‘000	9M 2025	9M 2024
Revenues	269,602	204,528
Costs of sales	(24,366)	(23,186)
Gross profit	245,236	181,342
Other income	2,303	2,034
Research and development	(68,221)	(60,839)
General and administrative	(59,945)	(45,999)
Marketing and sales	(99,746)	(91,863)
Other Operating Costs	(227,911)	(198,701)
Operating profit (loss)	19,628	(15,325)
Fair value gain (loss) on revaluation	—	5,159
Other finance income	1,748	3,760
Other finance expenses	(13,048)	(7,488)
Finance result, net	(11,300)	1,431
Share of net profits (loss) in associates using the equity method	(279)	(1,276)
Profit (loss) before tax	8,049	(15,170)
Income tax credit (expense)	(10,838)	470
Profit (loss) for the period	(2,790)	(14,700)
Attributable to:
Equity holders of the parent	(2,477)	(14,700)
Non-controlling interests	(313)	—
Earnings per share
Basic, attributable to equity holders of the parent (US$)	(0.004)	(0.022)
Diluted, attributable to equity holders of the parent (US$)	(0.004)	(0.022)

CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME
For the period ended September 30
Amounts in US$ ‘000	9M 2025	9M 2024
Profit (loss) for the period	(2,790)	(14,700)
Currency translation differences	26,092	(1,352)
Items that may be subsequently reclassified to profit or loss	26,092	(1,352)
Fair value remeasurement investments	—	79
Items that shall not be subsequently reclassified to profit or loss	—	79
Other comprehensive income (loss), net of tax	26,092	(1,273)
Total comprehensive income (loss) for the period	23,303	(15,973)
Attributable to:
Equity holders of the parent	23,616	(15,973)
Non-controlling interests	(313)	—

CONDENSED CONSOLIDATED INTERIM BALANCE SHEET
Amounts in US$ ‘000	September 30, 2025	December 31, 2024
Non-current assets
Intangible assets	134,926	61,039
Property, plant and equipment	7,475	7,752
Right-of-use assets	17,517	16,382
Long-term prepayments	95	90
Deferred tax assets	27,485	30,544
Investment accounted for using the equity method	1,005	466
Investment in equity instruments designated as at FVTOCI	1,394	—
Investment in debt instruments designated as at FVTPL	4,274	3,767
Restricted cash	2,015	1,505
Total non-current assets	196,185	121,545
Current assets
Inventories	67,136	55,724
Trade and other receivables	43,606	54,823
Restricted cash	690	0
Marketable securities	33,798	112,949
Cash and cash equivalents	132,370	54,944
Total current assets	277,600	278,440
Total assets	473,785	399,985
Equity
Share capital	7,953	7,769
Share premium	507,717	488,990
Other reserves	25,852	(209)
Accumulated deficit	(276,878)	(275,489)
Shareholders’ equity	264,644	221,061
Non-current liabilities
Convertible bonds	93,138	78,154
Lease liabilities	28,090	26,968
Total non-current liabilities	121,227	105,122
Current liabilities
Convertible bonds	5,210	4,245
Trade and other payables	78,221	66,611
Lease liabilities	4,484	2,946
Total current liabilities	87,914	73,802
Total equity and liabilities	473,785	399,985

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY
For the period ended September 30
Attributable to owners of the parent
Amounts in US$ ‘000	Share capital	Share premium	Other reserves	Accumulated deficit	Total	Non-controlling interests	Total equity
Balance at January 1, 2024	7,669	478,431	(2,057)	(265,262)	218,781	—	218,781
Profit (loss) for the period	—	—	—	(14,700)	(14,700)	—	(14,700)
Reserves	—	—	1,560	(1,560)	—	—	—
Other comprehensive income (loss) for the period	—	—	(1,273)	—	(1,273)	—	(1,273)
Total comprehensive income (loss) for the period	—	—	287	(16,260)	(15,973)	—	(15,973)
Other reserves	—	—	(31)	31	—	—	—
Income tax benefit from excess tax deductions related to share-based payments	—	—	—	(241)	(241)	—	(241)
Share-based compensation	—	—	—	8,605	8,605	—	8,605
Options exercised / LTIP shares issued	81	8,648	—	(5,244)	3,485	—	3,485
Value of conversion rights of convertible bonds	—	—	11,135	—	11,135	—	11,135
Total transactions with owners, recognized directly in equity	81	8,648	11,104	3,151	22,984	—	22,984
Balance at September 30, 2024	7,750	487,079	9,334	(278,371)	225,792	—	225,792
Balance at January 1, 2025	7,769	488,990	(209)	(275,489)	221,061	—	221,061
Profit (loss) for the period	—	—	—	(2,477)	(2,477)	(313)	(2,790)
Reserves	—	—	—	—	—	—	—
Other comprehensive income (loss) for the period	—	—	26,092	—	26,092	—	26,092
Total comprehensive income (loss) for the period	—	—	26,092	(2,477)	23,616	(313)	23,303
Other reserves	—	—	(32)	32	—	—	—
Income tax benefit from excess tax deductions related to share-based payments	—	—	—	807	807	—	807
Share-based compensation	—	—	—	9,256	9,256	—	9,256
Options exercised / LTIP shares issued	184	18,727	—	(8,320)	10,592	—	10,592
Value of conversion rights of convertible bonds	—	—	—	—	—	—	—
Acquisition of a subsidiary	—	—	—	—	—	7,741	7,741
Acquisition of non-controlling interests	—	—	—	(687)	(687)	(7,428)	(8,115)
Total transactions with owners, recognized directly in equity	184	18,727	(32)	1,087	19,967	313	20,280
Balance at September 30, 2025	7,953	507,717	25,852	(276,878)	264,644	—	264,644

CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS
For the period ended September 30
Amounts in $’000	9M 2025	9M 2024
Profit (loss) before tax	8,049	(15,170)
Adjustments to reconcile net profit (loss) to net cash used in operating activities:
Depreciation, amortization, impairment of non-current assets	8,010	8,371
Equity settled share based payments	9,256	8,605
Fair value loss (gain) on revaluation	—	(5,159)
Loss (gain) on disposal of leases	(9)	—
Other finance income	(1,748)	(3,117)
Other finance expenses	12,837	6,765
Share of net result in associates using the equity method	279	1,276
Operating cash flows before changes in working capital	36,674	1,571
Changes in working capital:
Inventories	(3,503)	(5,248)
Trade and other receivables	11,453	(2,044)
Payables and other current liabilities	4,138	4,305
Restricted cash	(1,018)	—
Total changes in working capital	11,070	(2,987)
Interest received	1,723	4,154
Income taxes received (paid)	(5,466)	(13,864)
Net cash flows generated from (used in) operating activities	44,001	(11,126)
Capital expenditure for property, plant and equipment	(480)	(660)
Investment intangible assets	(6)	—
Disposal of investment designated as at FVOCI	—	1,972
Investment in associates using the equity method	(731)	—
Purchases of marketable securities	—	(222,249)
Proceeds from sale of marketable securities	84,990	262,345
Acquisition of a subsidiary, net of cash acquired	(57,476)	—
Net cash flows generated from (used in) investing activities	26,297	41,408
Payment of lease liabilities	(2,877)	(2,485)
Interests on lease liabilities	(848)	(784)
Net proceeds of issued convertible bonds	—	104,539
Repurchase of convertible bonds	—	(134,931)
Interests on convertible bonds	(2,506)	(2,032)
Settlement of share based compensation awards	14,564	3,485
Acquisition of non-controlling interests	(7,876)
Net cash flows generated from (used in) financing activities	457	(32,208)
Increase (decrease) of cash	70,755	(1,926)
Exchange rate effects	6,672	847
Cash and cash equivalents at the beginning of the period	54,944	61,741
Total cash and cash equivalents at September 30	132,370	60,662

Attachment

• Pharming Group reports 3Q 2025 financial results_EN_06NOV25

HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA- directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten public offering of 5,930,000 shares of its common stock and a concurrent registered direct offering of 1,481,481 shares of its common stock with long-term investor Suvretta Capital. Each share of common stock is being sold at an offering price of $13.50. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 889,500 shares of common stock on the same terms and conditions. The offerings are expected to close on November 7, 2025, subject to customary closing conditions.

The aggregate gross proceeds to Benitec from the underwritten public offering and the concurrent registered direct offering are expected to be approximately $100 million, prior to deducting underwriting discounts, commissions, placement agent fees and other offering expenses.

The Company intends to use the net proceeds from this financing, together with existing cash on hand, to support the continued development of its product candidate programs, working capital and other general corporate purposes.

Leerink Partners, TD Cowen and Evercore ISI are acting as bookrunning managers for the underwritten public offering and as placement agents for the concurrent registered direct offering.

The Securities and Exchange Commission (“SEC”) declared effective a registration statement on Form S-3 relating to these securities on September 29, 2025. A prospectus supplement relating to these offerings will be filed with the SEC. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, from Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected]. Investors may also obtain these documents at no cost by visiting the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Benitec
Biopharma
Inc.

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD).

Cautionary
Note
Concerning
Forward-Looking
Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to the timing and completion of the public offering and the concurrent registered direct offering and the anticipated gross proceeds from the offering. No assurance can be given that the offerings discussed above will be completed on the terms described, or at all, or that the proceeds of the offerings will be used as indicated. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Benitec’s filings with the SEC. Benitec’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Benitec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Benitec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor
Relations
Contacts:

Irina Koffler
LifeSci Advisors, LLC
Phone: (917) 734-7387
Email: [email protected]

Source: Benitec Biopharma Inc.

(All amounts are expressed in US dollars, tabular amounts in millions, unless otherwise stated)

VANCOUVER, British Columbia, Nov. 05, 2025 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI)(“Fortuna” or the “Company”) today reported its financial and operating results for the third quarter of 2025.
^{(Results from the Company’s San Jose and Yaramoko assets have been excluded from its Q3 2025 continuing results, along with the comparative figures, due to the classification of the assets as discontinued as at June 30, 2025.)}

Jorge A. Ganoza President and CEO of Fortuna, commented, “Fortuna delivered a strong third quarter, keeping us on track to meet our annual production guidance. Higher gold prices and consistent mine performance generated $73.4 million in free cash flow from operations—up $16.0 million from Q2.” Mr. Ganoza continued, “Cash costs remained below $1,000/oz, and AISC at our mines is tracking within guidance. Lindero’s AISC is trending lower, and we expect similar improvements at Séguéla as it completes key investments to support 2026 production of 160,000–180,000 ounces.” Mr. Ganoza concluded, “Our balance sheet continues to strengthen, with nearly $600 million in liquidity and $265.8 million in net cash. This positions us to fund high-impact growth initiatives, including Diamba Sud, unlocking the full potential of the Séguéla Mine, and expanding exploration across West Africa and Latin America.”

Third Quarter 2025 Highlights

Cash and Cashflow

• Free cash flow¹ from ongoing operations of $73.4 million, and net cash from operating activities before changes in working capital of $113.9 million or $0.37 per share. The quarter included $13.6 million in withholding taxes paid related to the repatriation of $118.2 million from Argentina and Côte d’Ivoire
• Liquidity increased to $588.3 million, and the net cash¹ position strengthened to $265.8 million, from $214.8 million in Q2 2025
• Quarter-end cash balance of $438.3 million, an increase of $51.0 million QoQ

Profitability

• Attributable net income from continuing operations of $123.6 million or $0.40 per share, a QoQ increase of $0.26
• Adjusting for impairment reversals at Lindero, attributable adjusted net income¹ from continuing operations was $51.0 million or $0.17 per share, a QoQ increase of $0.02. Results include the impact of $0.04 per share from a $6.3 million increase in share-based compensation (“SBC”) expense, due to the rise in share price, and a $7.4 million FX loss
• Adjusted EBITDA margin¹ was 52%, compared to 56% in Q2 2025. QoQ, excluding the impact of higher SBC and FX gains/losses, the EBITDA margin improved from 55% to 58%

Operational

• Gold equivalent production (“GEO”) of 72,462 ounces from continuing operations²
• Consolidated cash cost per GEO¹ from continuing operations of $942, compared to $929 in Q2 2025
• Consolidated AISC per GEO¹ from continuing operations of $1,987 compared to $1,932 in Q2 2025. AISC includes a one-time impact of $80 related to a higher SBC expense
• Year-to-date TRIFR of 0.86 reflects continued strong safety performance; zero lost time injuries in the quarter

Growth and Business Development

• Completed a Preliminary Economic Assessment (“PEA”) for the Diamba Sud Gold Project, confirming robust project economics for the development of an open-pit mine and conventional carbon-in-leach processing plant. Refer to Fortuna news release dated October 15, 2025, “Fortuna delivers robust PEA for Diamba Sud Gold Project in Senegal: After-tax IRR of 72% and NPV5% of US$563 million using US$2,750 per ounce” 
• Advancing the Diamba Sud project towards a Definitive Feasibility Study and a construction decision in the first half of 2026
  _{Cautionary Statement: The PEA is preliminary in nature, and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves; as such, there is no certainty that the PEA results will be realized. Mineral resources that are not mineral reserves do not have demonstrated economic viability.³}

<sub>¹  Refer to Non-IFRS Financial Measures section at the end of this news release and to the MD&A accompanying the Company’s financial statements filed on SEDAR+ at www.sedarplus.ca for a description of the calculation of these measures


²  Au Eq includes gold, silver, lead and zinc and is calculated using the following metal prices: $3,467/oz Au, $39.4/oz Ag, $1,962/t Pb and $2,815/t Zn for Q3 2025; $2,498/oz Au, $29.2/oz Ag, $2,040/t Pb and $2,782/t Zn for Q3 2024; $3,306/oz Au, $33.8/oz Ag, $1,945/t Pb, and $2,640/t Zn for Q2 2025
³  Refer to the table on page 26 of this news release for a summary of the key assumptions, operational parameters and economic results and values from the PEA</sub>

Third Quarter 2025 Consolidated Results

		Three months ended						Nine months ended September 30,
($ Expressed in millions)		Sept 30, 2025		Sept 30, 2024		June 30, 2025		2025	2024			% Change
Total production including discontinued operations (GEO)		72,462		110,820		75,950		251,871		339,933		(26	%)
Production from continuing operations (GEO)		72,462		73,123		71,229		214,077		216,801		(1	%)
Financial Highlights from Continuing Operations
Sales		251.4		181.7		230.4		676.8		482.0		40	%
Mine operating income		133.1		64.1		105.0		318.5		164.3		94	%
Operating income		154.6		50.8		83.7		294.3		110.4		167	%
Net income from continuing operations		128.2		37.4		47.7		214.8		74.0		190	%
Attributable net income from continuing operations		123.6		35.5		42.6		201.7		69.8		189	%
Attributable earnings per share from continuing operations – basic		0.40		0.11		0.14		0.66		0.23		187	%
Adjusted attributable net income from continuing operations1		51.0		32.7		44.7		131.7		57.8		128	%
Adjusted attributable net income from continuing operations earnings per share		0.17		0.10		0.15		0.43		0.19		126	%
Adjusted EBITDA1		130.8		96.6		127.7		356.6		236.4		51	%
Net cash provided by operating activities – continuing operations		111.3		67.3		92.7		293.0		136.5		115	%
Free cash flow from ongoing operations1		73.4		34.0		57.4		197.5		51.5		283	%
Cash cost ($/oz GEO)1		942		906		929		915		831		10	%
AISC continuing ops($/oz GEO)1,2		1,987		1,638		1,932		1,896		1,558		22	%
AISC including discontinued ops($/oz GEO)1,2,3		1,987		1,669		1,899		1,822		1,593		14	%
Capital expenditures2
Sustaining		31.2		33.7		31.4		85.2		81.4		5	%
Sustaining leases		6.5		2.9		6.0		17.4		10.7		63	%
Growth capital		17.4		7.3		15.6		48.4		28.1		72	%
								Sept 30, 2025		Dec 31, 2024		% Change
Cash and cash equivalents and short-term investments								438.3		231.3		89	%
Net liquidity position (excluding letters of credit)								588.3		381.3		54	%
Shareholder’s equity attributable to Fortuna shareholders								1,618.9		1,403.9		15	%
1 Refer to Non-IFRS Financial Measures section at the end of this news release and to the MD&A accompanying the Company’s financial statements filed on SEDAR+ at www.sedarplus.ca for a description of the calculation of these measures.
2 Capital expenditures are presented on a cash basis
3 Year to date 2025 AISC reflects production and costs for Yaramoko from April 1 to April 14, 2025, being the date that the Company agreed to the assumed handover of operations to the purchaser. AISC per ounce of gold equivalent sold for the aforementioned period has been estimated at $1,410 which is comparable to the AISC per ounce of gold equivalent sold at Yaramoko for Q1 2025 of $1,411
Figures may not add due to rounding
Contribution from discontinued operations, the Yaramoko and San Jose mines which were disposed of in the second quarter of 2025, have been removed where applicable

Third Quarter 2025 Results

Q3 2025 vs Q2 2025

Cash cost per ounce and AISC

Cash cost per GEO sold from continuing operations was $942 in Q3 2025, representing a marginal increase from the $929 recorded in Q2 2025.

All-in sustaining costs per GEO from continuing operations was $1,987 in Q3 2025 representing a $55 increase from the $1,932 recorded in Q2 2025. The rise was primarily driven by a one-time increase of $80 per GEO in share-based compensation. This expense resulted from the revaluation of cash-settled share units due to the higher share price during the quarter. The impact was partially offset by higher ounces sold.

Attributable Net Income and Adjusted Net Income

Attributable net income from continuing operations for the period was $123.6 million, compared to $42.6 million in Q2 2025. Net income reflects the reversal of an impairment charge of $52.7 million and a reversal of a previous write-down of $16.7 million of low-grade stockpiles at Lindero as a result of an increase in medium and long-term gold price projections

After adjusting for impairment reversals and other non-recurring items, adjusted attributable net income was $51.0 million or $0.17 per share compared to $44.7 million or $0.15 per share in Q2 2025. The increase was explained mainly by higher gold prices and higher gold sales volume, as well as a lower effective tax rate. The realized gold price in Q3 2025 was $3,467 per ounce compared to $3,307 in Q2 2025. The increase in gold sales volume was due to higher gold production at Lindero. The effective tax rate in Q3 2025 over adjusted net income was 30% compared to 40% in Q2 2025 due to the timing on recognition of withholding taxes related to dividend approvals in Côte d’Ivoire. This was partially offset by a foreign exchange loss of $7.4 million in Q3 compared to a gain of $2.3 million in Q2, and higher stock-based compensation of $10.8 million in Q3 compared to $4.5 million in Q2 related to the revaluation of cash-settled units from a higher share price.

Foreign exchange loss

In Q3 2025, the Company recorded a foreign exchange charge of $7.4 million compared to a gain of $2.3 million in Q2 2025. The main driver for this charge was a foreign exchange loss of $5.6 million at our Argentinean operations related to a 14% devaluation of the peso in the quarter. Year-to-date, the peso has devalued 32% generating a cumulative loss of $10 million. Over half of this year-to-date loss relates to cash accumulated in-country in the first half of 2025; however, this loss was fully offset by interest, investment, and derivative gains throughout the year. In early Q3 the Company was able to restart the repatriation of funds from Argentina, allowing us to keep local cash balances at a minimum.

Cash flow

Net cash generated by operations before changes in working capital was $113.9 million or $0.37 per share. After adjusting for changes in working capital, net cash generated by operations for the quarter was $111.3 million compared to $92.7 million in Q2 2025 driven by higher sales. Income taxes of $34.7 million were comparable to the $36.4 million paid in Q2 2025 due to a final installment payment of $15.4 million at Séguéla as well as $13.6 million in withholding taxes paid for the repatriation of funds from Argentina and Côte d’Ivoire.

Free cash flow from ongoing operations in Q3 2025 was $73.4 million, an increase of $16.0 million over the $57.4 million reported in Q2 2025 reflecting higher sales and cash from operating activities. Sustaining capital expenditures for the quarter were $31.2 million, broadly in line with Q2 2025.

In Q3 2025 the Company invested $17.4 million in non-sustaining capital expenditures; primarily consisting of $9.8 million in mine site exploration, $1.1 million in other mine site projects, and $6.5 million at the Diamba Sud Gold Project.

Q3 2025 vs Q3 2024

Cash cost per ounce and AISC

Consolidated cash cost per GEO increased to $942 in Q3 2025, representing a $36 increase compared the $906 recorded in Q3 2024. This increase was mainly due to higher mine stripping ratios at Séguéla and Lindero, as per the mine plan, and lower gold equivalent ounces at Caylloma due to an increase in the gold price and the impact on gold equivalent ounces.

All-in sustaining costs per gold equivalent ounce from continuing operations increased to $1,987 in Q3 2025 from $1,638 in Q3 2024. This increase primarily resulted from the higher cash cost per ounce discussed above and higher capital leases, higher share-based compensation expense from the impact of the rise in our share price in Q3 2025, and increased royalties due to the higher gold price. Additionally, the previous period also benefited from ($43)/oz related to blue chip swaps in Argentina, compared to $nil in Q3 2025.

Attributable Net Income and Adjusted Net Income

Attributable net income from continuing operations for the period was $123.6 million, or $0.40 per share, compared to $35.5 million, or $0.11 per share, in Q3 2024. After adjusting for reversals of impairments and stockpile write-downs of $69.4 million at Lindero and other non-recurring items, adjusted attributable net income was $51.0 million or $0.17 per share compared to $32.7 million or $0.10 per share in Q3 2024. The increase was primarily due to higher realized gold prices, which averaged $3,467 per ounce in Q3 2025 compared to $2,498 per ounce in Q3 2024 and higher sales volumes at Séguéla driven by higher processes ore and grades. This was partially offset by higher stock-based compensation and a $7.4 million foreign exchange loss (see discussion above) compared to a $1.1 million gain in Q3 2024.

Depreciation and Depletion

Depreciation and depletion increased by $7.2 million to $53.0 million compared to $45.8 million in the comparable period of 2024. The increase was primarily due to higher ounces sold at Séguéla and an increase in the depletion per ounce at Lindero due to added depletion from the leach pad expansion project and the construction of the solar plant. Depreciation and depletion in the period included $18.7 million related to the purchase price allocation from the Roxgold acquisition in 2021.

Cash Flow

Net cash generated by operations for the quarter was $111.3 million compared to $67.3 million in Q3 2024. The increase is mainly explained by higher gold prices and higher gold volume sold at Séguéla, and a lower negative change in working capital in Q3 2025 compared to Q3 2024.

Free cash flow from ongoing operations in Q3 2025 was $73.4 million, compared to $30.4 million reported in Q3 2024. The increase was mainly due to higher prices and metal sold as discussed above. Sustaining capital expenditures for the quarter were $31.2 million, mostly consistent with Q3 2024.

Séguéla Mine, Côte d’Ivoire

			Three months ended September 30,						Nine months ended September 30,
			2025			2024			2025			2024
Mine Production
Tonnes milled			435,770			418,390			1,308,958			1,131,684
Average tonnes crushed per day			4,737			4,548			4,777			4,115
Gold
Grade (g/t)			3.01			2.69			2.92			2.94
Recovery (%)			91			92			92			93
Production (oz)			38,799			34,998			115,485			102,537
Metal sold (oz)			38,803			33,816			115,386			101,369
Realized price ($/oz)			3,462			2,494			3,222			2,305
Unit Costs
Cash cost ($/oz Au)1			688			655			669			559
All-in sustaining cash cost ($/oz Au)1			1,738			1,176			1,554			1,073
Capital Expenditures ($000’s)2
Sustaining			21,355			6,209			48,033			21,100
Sustaining leases			4,270			2,332			12,393			7,034
Growth capital			7,893			4,797			22,638			14,437
1 Cash cost and All-in sustaining cash cost are non-IFRS financial measures. Refer to Non-IFRS Financial Measures.
2 Capital expenditures are presented on a cash basis

Quarterly Operating and Financial Highlights

During the third quarter of 2025, mine production totaled 272,396 tonnes of ore, averaging 3.66 g/t Au, and containing an estimated 32,074 ounces of gold from the Antenna, Ancien, and Koula pits. The lower ore tonnes mined compared to milled tonnes are in line with the mine plan and strategy to reduce surface stockpiles. A total of 4,433,994 tonnes of waste was moved during the period, resulting in a strip ratio of 16.3:1.

In the third quarter of 2025, Séguéla processed 435,770 tonnes of ore, producing 38,799 ounces of gold, at an average head grade of 3.01 g/t Au, an 11% and a 12% increase, respectively, compared to the third quarter of 2024. Higher gold production was the result of higher tonnes processed and higher grades.

Cash cost per gold ounce sold was $688 for the third quarter of 2025 compared to $655 for the third quarter of 2024. Cash costs were aligned as higher ounces sold offset an increase in mining costs from higher stripping requirements in line with the mine plan.

All-in sustaining cash cost per gold ounce sold was $1,738 for the third quarter of 2025 compared to $1,176 in the same period of the previous year. The increase for the quarter was primarily the result of higher sustaining capital from capitalized stripping and higher royalties due to higher gold prices and a 2% increase in the royalty rate effective January 10, 2025.

Lindero Mine, Argentina

			Three months ended September 30,						Nine months ended September 30,
			2025			2024			2025			2024
Mine Production
Tonnes placed on the leach pad			1,699,007			1,654,101			5,280,543			4,610,215
Gold
Grade (g/t)			0.60			0.66			0.57			0.62
Production (oz)			24,417			24,345			68,287			70,481
Metal sold (oz)			25,290			26,655			67,433			69,886
Realized price ($/oz)			3,476			2,503			3,246			2,316
Unit Costs
Cash cost ($/oz Au)1			1,117			1,042			1,136			1,047
All-in sustaining cash cost ($/oz Au)1			1,570			1,842			1,738			1,762
Capital Expenditures ($000’s)2
Sustaining			7,153			20,678			30,871			46,636
Sustaining leases			1,279			586			2,652			1,771
Growth capital			1,174			219			3,308			568
1 Cash cost and All-in sustaining cash cost are non-IFRS financial measures; refer to non-IFRS financial measures section at the end of this news release and to the MD&A accompanying the Company’s financial statements filed on SEDAR+ at www.sedarplus.ca for a description of the calculation of these measures.
2 Capital expenditures are presented on a cash basis.

Quarterly Operating and Financial Highlights

In the third quarter of 2025, a total of 1,699,007 tonnes of ore were placed on the heap leach pad, with an average gold grade of 0.60 g/t, containing an estimated 32,775 ounces of gold. Ore mined was 1.50 million tonnes, with a stripping ratio of 1.9:1.

Lindero’s gold production for the quarter was 24,417 ounces, comprised of 23,001 ounces in doré bars, 1,325 ounces contained in rich fine carbon and 91 ounces contained in copper precipitate. Gold production remained comparable to the third quarter of 2024, as the slight increase in tonnes placed on the leach pad was offset by lower ore mined and lower gold grade in the third quarter of 2025.

The cash cost per ounce of gold for the quarter was $1,117 compared to $1,042 in the same period of 2024. The increase in cash costs was primarily driven by lower ounces sold.

AISC per gold ounce sold during Q3 2025 was $1,570 compared to $1,842 in Q3 2024. Lower AISC was primarily due to lower sustaining capital expenditures as the leach pad expansion was under construction in the comparable quarter. The comparable quarter also benefited from $3.2 million of investment gains from cross border Argentine pesos denominated bond trades compared to $nil in the current quarter.

On September 27, 2025, the primary crusher experienced an unplanned, immediate shutdown. The cause was determined to be a mechanical failure involving high amperage and overheating of the pitman shaft, specifically traced to the premature wear of the primary wear parts: the bushings and bearings.

Replacement wear parts have been successfully sourced. Management’s current assessment indicates that the early failure of the bushings and bearings was likely caused by a misalignment of structural components. This issue is being fully addressed and corrected prior to the reassembly and commissioning of the crusher. The primary crusher is anticipated to be operational by the second half of November 2025.

Despite this unexpected downtime, Management does not anticipate an impact to the annual production guidance for the Lindero Mine. Immediate mitigating measures have been implemented to maintain throughput, including bypassing the primary crusher entirely with the deployment of a portable jaw crusher, and direct Run-of-Mine ore screening.

Caylloma Mine, Peru

			Three months ended September 30,							Nine months ended September 30,
			2025			2024				2025			2024
Mine Production
Tonnes milled			140,523			138,030				415,653			411,669
Average tonnes milled per day			1,561			1,551				1,557			1,548
Silver
Grade (g/t)			63			82				65			84
Recovery (%)			82			84				83			83
Production (oz)			233,612			305,446				717,226			927,304
Metal sold (oz)			238,527			338,768				736,240			931,820
Realized price ($/oz)			39.33			29.24				34.89			26.98
Lead
Grade (%)			3.01			3.62				3.15			3.64
Recovery (%)			91			91				91			91
Production (000’s lbs)			8,492			9,998				26,253			30,053
Metal sold (000’s lbs)			8,628			10,934				27,010			30,181
Realized price ($/lb)			0.89			0.93				0.89			0.95
Zinc
Grade (%)			4.27			4.64				4.63			4.63
Recovery (%)			91			91				91			90
Production (000’s lbs)			11,989			12,809				38,612			38,032
Metal sold (000’s lbs)			12,259			13,411				38,368			38,586
Realized price ($/lb)			1.28			1.26				1.26			1.22
Unit Costs
Cash cost ($/oz Ag Eq)1,2			17.92			14.88				15.19			13.45
All-in sustaining cash cost ($/oz Ag Eq)1,2			25.17			22.69				21.76			19.90
Capital Expenditures ($000’s)3
Sustaining			2,659			6,826				6,261			13,688
Sustaining leases			945			(9	)			2,317			1,871
Growth capital			702			–				1,256			–
1 Cash cost per ounce of silver equivalent and All-in sustaining cash cost per ounce of silver equivalent are calculated using realized metal prices for each period respectively.
2 Cash cost per ounce of silver equivalent, and all-in sustaining cash cost per ounce of silver equivalent are non-IFRS financial measures, refer to non-IFRS financial measures section at the end of this news release and to the MD&A accompanying the Company’s financial statements filed on SEDAR+ at www.sedarplus.ca for a description of the calculation of these measures.
3 Capital expenditures are presented on a cash basis.

Quarterly Operating and Financial Highlights

In the third quarter of 2025, the Caylloma Mine produced 233,612 ounces of silver at an average head grade of 63 g/t, a 24% decrease when compared to the same period in 2024.

Lead and zinc production for the quarter was 8.5 million pounds and 12.0 million pounds, respectively. Head grades averaged 3.01% Pb and 4.27% Zn, a 7% and 8% decrease, respectively, when compared to the same quarter in 2024. Production was lower due to lower head grades and was in line with the mine plan.

The cash cost per silver equivalent ounce sold in the third quarter of 2025 was $17.92 compared to $14.88 in the same period in 2024. The higher cost per ounce for the quarter was primarily the result of lower silver production and the impact of higher realized silver prices on the calculation of silver equivalent ounce sold.

The all-in sustaining cash cost per ounce of payable silver equivalent in the third quarter of 2025 increased 11% to $25.17 compared to $22.69 for the same period in 2024. The increase for the quarter was the result of higher cash costs per ounce and lower silver equivalent ounces due to higher silver prices.

Qualified Person
Eric Chapman, Senior Vice President of Technical Services, is a Professional Geoscientist of the Association of Professional Engineers and Geoscientists of the Province of British Columbia (Registration Number 36328), and is the Company’s Qualified Person (as defined by National Instrument 43-101). Mr. Chapman has reviewed and approved the scientific and technical information contained in this news release and has verified the underlying data.

Non-IFRS Financial Measures
The Company has disclosed certain financial measures and ratios in this news release which are not defined under the International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board, and are not disclosed in the Company’s financial statements, including but not limited to: all-in costs; cash cost per ounce of gold sold; all-in sustaining costs; all-in sustaining cash cost per ounce of gold sold; all-in sustaining cash cost per ounce of gold equivalent sold; all-in cash cost per ounce of gold sold; production cash cost per ounce of gold equivalent; cash cost per payable ounce of silver equivalent sold; all-in sustaining cash cost per payable ounce of silver equivalent sold; all-in cash cost per payable ounce of silver equivalent sold; sustaining capital; growth capital; free cash flow from ongoing operations; adjusted net income; adjusted attributable net income; adjusted EBITDA, adjusted EBITDA margin and working capital.

These non-IFRS financial measures and non-IFRS ratios are widely reported in the mining industry as benchmarks for performance and are used by management to monitor and evaluate the Company’s operating performance and ability to generate cash. The Company believes that, in addition to financial measures and ratios prepared in accordance with IFRS, certain investors use these non-IFRS financial measures and ratios to evaluate the Company’s performance. However, the measures do not have a standardized meaning under IFRS and may not be comparable to similar financial measures disclosed by other companies. Accordingly, non-IFRS financial measures and non-IFRS ratios should not be considered in isolation or as a substitute for measures and ratios of the Company’s performance prepared in accordance with IFRS.

To facilitate a better understanding of these measures and ratios as calculated by the Company, descriptions are provided below. In addition see “Non-IFRS Financial Measures” in the Company’s management’s discussion and analysis for the three and nine months ended September 30, 2025 (“Q3 2025 MDA”), which section is incorporated by reference in this news release, for additional information regarding each non-IFRS financial measure and non-IFRS ratio disclosed in this news release, including an explanation of their composition; an explanation of how such measures and ratios provide useful information to an investor. The Q3 2025 MD&A may be accessed on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov/edgar under the Company’s profile.

The Company has calculated these measures consistently for all periods presented with the exception of the following:

• The calculation of All-in Sustaining Costs was adjusted in Q4 2024 to include blue-chip swaps in Argentina. Please refer to pages 28 and 29 of the Company’s management’s discussion and analysis for the year ended December 31, 2024 for details of the change.
• The calculations of Adjusted Net Income and Adjusted Attributable Net Income were revised to no longer remove the income statement impact of right of use amortization and accretion and add back the right of use payments from the cash flow statement. Management elected to make this change to simplify the reconciliation from net income to adjusted net income to improve transparency and because the net impact was immaterial.
• Where applicable the impact of discontinued operations have been removed from the comparable figures. The method of calculation has not been changed except as described above.

Reconciliation of Debt to total net debt and net debt to adjusted EBITDA ratio for September 30, 2025

(Expressed in millions except Total net debt to Adjusted EBITDA ratio)	As at September 30, 2025
2024 Convertible Notes	172.5
Less: Cash and Cash Equivalents and Short-term Investments	(438.3	)
Total net debt1	(265.8	)
Adjusted EBITDA (last four quarters)	461.7
Total net debt to adjusted EBITDA ratio	(0.6):1
1 Excluding letters of credit

Reconciliation of net income to attributable adjusted net income for the three months ended June 30, 2025, and for the three and nine months ended September 30, 2025 and 2024

		Three months ended								Nine months ended September 30,
Consolidated (in millions of US dollars)		Sept 30, 2025			Sept 30, 2024			June 30, 2025		2025		2024
Net income attributable to shareholders		123.6			50.5			37.3		219.4			117.4
Adjustments, net of tax:
Discontinued operations		–			(17.0	)		3.6		(22.3	)		(52.8	)
Write off of mineral properties		–			–			2.0		2.0			–
Reversal of impairment of mineral properties, plant and equipment		(52.7	)		–			–		(52.7	)		–
Inventory adjustment		(16.7	)		–			–		(16.9	)		0.2
Other non-cash/non-recurring items		(3.2	)		(0.8	)		1.8		2.2			(7.0	)
Attributable Adjusted Net Income		51.0			32.7			44.7		131.7			57.8
Figures may not add due to rounding

Reconciliation of net income to adjusted EBITDA for the three months ended June 30, 2025 and the three and nine months ended September 30, 2025 and 2024

		Three months ended									Nine months ended September 30,
Consolidated (in millions of US dollars)		Sept 30, 2025			Sept 30, 2024			June 30, 2025			2025		2024
Net income		128.2			54.4			44.1			237.0			126.8
Adjustments:
Discontinued operations		–			(17.0	)		3.6			(22.3	)		(52.8	)
Inventory adjustment		(16.7	)		–			–			(16.9	)		–
Net finance items		3.2			5.7			3.4			9.6			15.5
Depreciation, depletion, and amortization		47.1			43.0			42.5			143.3			120.3
Income taxes		24.8			10.5			33.7			73.9			26.3
Reversal of impairment of mineral properties, plant and equipment		(52.7	)		–			–			(52.7	)		–
Investment income		(0.3	)		–			(1.7	)		(2.0	)		–
Other non-cash/non-recurring items		(2.8	)		–			2.1			(13.3	)		0.3
Adjusted EBITDA		130.8			96.6			127.7			356.6			236.4
Sales		251.4			181.7			230.4			676.8			482.0
EBITDA margin		52 %			53%			55%			53 %			49%
Figures may not add due to rounding

Reconciliation of net cash from operating activities to free cash flow from ongoing operations for the three months ended June 30, 2025 and the three and nine months ended September 30, 2025 and 2024

		Three months ended									Nine months ended September 30,
Consolidated (in millions of US dollars)		Sept 30, 2025			Sept 30, 2024			June 30, 2025			2025		2024
Net cash provided by operating activities		111.3			92.9			67.30			305.0			215.4
Additions to mineral properties, plant and equipment		(48.5	)		(42.1	)		(47.0	)		(135.1	)		(110.9	)
Payments of lease obligations		(6.6	)		(3.0	)		(6.4	)		(19.0	)		(11.3	)
Free cash flow		56.2			47.8			13.9			150.9			93.2
Growth capital		17.4			8.3			15.6			48.4			28.1
Discontinued operations		–			(25.6	)		26.2			(7.7	)		(78.9	)
Closure and rehabilitation provisions		0.1			–			–			0.2			–
Gain on blue chip swap investments		–			3.2			–			1.3			8.3
Other adjustments		(0.3	)		0.3			1.7			4.4			0.8
Free cash flow from ongoing operations		73.4			34.0			57.4			197.5			51.5
Figures may not add due to rounding

Reconciliation of cost of sales to cash cost per ounce of gold equivalent sold for the three months ended June 30, 2025 and the three and nine months ended September 30, 2025 and 2024

Cash Cost Per Gold Equivalent Ounce Sold – Q2 2025		Lindero			Séguéla			Caylloma			GEO Cash Costs
Cost of sales		40,939			66,660			17,793			125,394
Depletion, depreciation, and amortization		(13,331	)		(29,934	)		(4,268	)		(47,533	)
Royalties and taxes		(92	)		(11,152	)		(295	)		(11,539	)
By-product credits		(762	)		–			–			(762	)
Other		59			–			(663	)		(604	)
Treatment and refining charges		–			–			28			28
Cash cost applicable per gold equivalent ounce sold		26,813			25,574			12,595			64,982
Ounces of gold equivalent sold		23,350			38,144			8,484			69,978
Cash cost per ounce of gold equivalent sold ($/oz)		1,148			670			1,485			929
Gold equivalent was calculated using the realized prices for gold of $3,306/oz Au, $33.8/oz Ag, $1,945/t Pb and $2,640/t Zn for Q2 2025
Figures may not add due to rounding

Cash Cost Per Gold Equivalent Ounce Sold – Q3 2025		Lindero			Séguéla			Caylloma			GEO Cash Costs
Cost of sales		28,366			70,549			19,317			118,234
Depletion, depreciation, and amortization		(15,594	)		(31,716	)		(5,199	)		(52,509	)
Royalties and taxes		(83	)		(12,154	)		(287	)		(12,524	)
By-product credits		(1,264	)		–			–			(1,264	)
Other		16,675			–			(668	)		16,007
Treatment and refining charges		–			–			416			416
Cash cost applicable per gold equivalent ounce sold		28,100			26,679			13,579			68,358
Ounces of gold equivalent sold		25,157			38,803			8,601			72,561
Cash cost per ounce of gold equivalent sold ($/oz)		1,117			688			1,579			942
Gold equivalent was calculated using the realized prices for gold of $3,467/oz Au, $39.4/oz Ag, $1,962/t Pb and $2,815/t Zn for Q3 2025
Figures may not add due to rounding

Cash Cost Per Gold Equivalent Ounce Sold – Q3 2024		Lindero			Séguéla			Caylloma			GEO Cash Costs
Cost of sales		42,350			55,466			19,820			117,636
Depletion, depreciation, and amortization		(13,639	)		(27,165	)		(4,465	)		(45,269	)
Royalties and taxes		(89	)		(6,143	)		(366	)		(6,598	)
By-product credits		(1,132	)		–			–			(1,132	)
Other		3			–			(279	)		(276	)
Treatment and refining charges		–			–			2,249			2,249
Cash cost applicable per gold equivalent ounce sold		27,493			22,158			16,959			66,610
Ounces of gold equivalent sold		26,393			33,816			13,343			73,553
Cash cost per ounce of gold equivalent sold ($/oz)		1,042			655			1,271			906
Gold equivalent was calculated using the realized prices for gold of $2,498/oz Au, $29.2/oz Ag, $2,040/t Pb and $2,782/t Zn for Q3 2024
Figures may not add due to rounding

Cash Cost Per Gold Equivalent Ounce Sold – Year to Date 2025		Lindero			Séguéla			Caylloma			GEO Cash Costs
Cost of sales		101,110			202,634			54,573			358,319
Depletion, depreciation, and amortization		(38,724	)		(91,961	)		(13,836	)		(144,521	)
Royalties and taxes		(270	)		(33,439	)		(822	)		(34,531	)
By-product credits		(2,757	)		–			–			(2,757	)
Other		16,857			–			(1,991	)		14,866
Treatment and refining charges		–			–			494			494
Cash cost applicable per gold equivalent ounce sold		76,216			77,234			38,418			191,868
Ounces of gold equivalent sold		67,087			115,386			27,315			209,788
Cash cost per ounce of gold equivalent sold ($/oz)		1,136			669			1,406			915
Gold equivalent was calculated using the realized prices for gold of $3,231/oz Au, $34.9/oz Ag, $1,960/t Pb and $2,768/t Zn for Year to Date 2025
Figures may not add due to rounding

Cash Cost Per Gold Equivalent Ounce Sold – Year to Date 2024		Lindero			Séguéla			Caylloma			GEO Cash Costs
Cost of sales		112,407			152,106			53,164			317,677
Depletion, depreciation, and amortization		(36,800	)		(78,211	)		(11,647	)		(126,658	)
Royalties and taxes		(458	)		(17,244	)		(949	)		(18,651	)
By-product credits		(2,259	)		–			–			(2,259	)
Other		(226	)		–			(960	)		(1,186	)
Treatment and refining charges		–			–			5,766			5,766
Cash cost applicable per gold equivalent ounce sold		72,664			56,651			45,374			174,689
Ounces of gold equivalent sold		69,430			101,369			39,399			210,198
Cash cost per ounce of gold equivalent sold ($/oz)		1,047			559			1,152			831
Gold equivalent was calculated using the realized prices for gold of $2,310/oz Au, $27.0/oz Ag, $2,091/t Pb and $2,692/t Zn for Year to Date 2024
Figures may not add due to rounding

Reconciliation of cost of sales to all-in sustaining cash cost per ounce of gold equivalent sold from continuing operations for the three months ended June 30, 2025 and the three and nine months ended September 30, 2025 and 2024

For Q2 2025 and year to date 2025 AISC reflects production and costs for Yaramoko from April 1 to April 14, 2025, being the date that the Company agreed to the assumed handover of operations to the purchaser. AISC per ounce of gold equivalent sold for the aforementioned period has been estimated at $1,410 which is comparable to the AISC per ounce of gold equivalent sold at Yaramoko for Q1 2025 of $1,411.

		Continuing Operations										Discontinued Ops		Total
AISC Per Gold Equivalent Ounce Sold – Q2 2025		Lindero		Séguéla		Caylloma		Corporate		GEO AISC		Yaramoko		GEO AISC
Cash cost applicable per gold equivalent ounce sold		26,813		25,574		12,595		–		64,982		5,000		69,982
Royalties and taxes		92		11,152		295		–		11,539		1,105		12,644
Worker’s participation		–		–		760		–		760		–		760
General and administration		2,577		3,038		1,672		13,175		20,462		238		20,700
Total cash costs		29,482		39,764		15,322		13,175		97,743		6,343		104,086
Sustaining capital1		12,147		22,549		2,729		–		37,425		314		37,739
Blue chips gains (investing activities)1		–		–		–		–		–		–		–
All-in sustaining costs		41,629		62,313		18,051		13,175		135,168		6,657		141,825
Gold equivalent ounces sold		23,350		38,144		8,484		–		69,978		4,721		74,699
All-in sustaining costs per ounce		1,783		1,634		2,128		–		1,932		1,410		1,899
Gold equivalent was calculated using the realized prices for gold of $3,306/oz Au, $33.8/oz Ag, $1,945/t Pb and $2,640/t Zn for Q2 2025
Figures may not add due to rounding
1 Presented on a cash basis

AISC Per Gold Equivalent Ounce Sold – Q3 2025		Lindero		Séguéla		Caylloma		Corporate		GEO AISC
Cash cost applicable per gold equivalent ounce sold		28,100		26,679		13,579		–		68,358
Inventory net realizable value adjustment		–		–		–		–		–
Royalties and taxes		83		12,154		287		–		12,524
Worker’s participation		–		–		777		–		777
General and administration		2,880		2,993		830		18,163		24,866
Total cash costs		31,063		41,826		15,473		18,163		106,525
Sustaining capital1		8,432		25,625		3,604		–		37,661
Blue chips gains (investing activities)1		–		–		–		–		–
All-in sustaining costs		39,495		67,451		19,077		18,163		144,186
Gold equivalent ounces sold		25,157		38,803		8,601		–		72,561
All-in sustaining costs per ounce		1,570		1,738		2,218		–		1,987
Gold equivalent was calculated using the realized prices for gold of $3,467/oz Au, $39.4/oz Ag, $1,962/t Pb and $2,815/t Zn for Q3 2025
Figures may not add due to rounding
1 Presented on a cash basis

		Continuing Operations												Discontinued Ops				Total
AISC Per Gold Equivalent Ounce Sold – Q3 2024		Lindero			Séguéla		Caylloma		Corporate		GEO AISC			Yaramoko		San Jose		GEO AISC
Cash cost applicable per gold equivalent ounce sold		27,492			22,158		16,959		–		66,609			27,253		23,875		117,737
Inventory net realizable value adjustment		–			–		–		–		–			–		–		–
Royalties and taxes		89			6,143		366		–		6,598			5,480		639		12,717
Worker’s participation		–			–		472		–		472			–		–		472
General and administration		2,935			2,945		1,246		6,275		13,401			550		1,802		15,753
Total cash costs		30,516			31,246		19,043		6,275		87,080			33,283		26,316		146,679
Sustaining capital1		21,264			8,511		6,817		–		36,592			5,166		198		41,956
Blue chips gains (investing activities)1		(3,162	)		–		–		–		(3,162	)		–		–		(3,162	)
All-in sustaining costs		48,618			39,757		25,860		6,275		120,510			38,449		26,514		185,473
Gold equivalent ounces sold		26,393			33,816		13,343		–		73,553			27,995		9,597		111,145
All-in sustaining costs per ounce		1,842			1,176		1,938		–		1,638			1,373		2,763		1,669
Gold equivalent was calculated using the realized prices for gold of $2,333/oz Au, $28.5/oz Ag, $2,157/t Pb and $2,835/t Zn for Q3 2024
Figures may not add due to rounding
1 Presented on a cash basis

		Continuing Operations												Discontinued Ops		Total
AISC Per Gold Equivalent Ounce Sold – Year to Date 2025		Lindero			Séguéla		Caylloma		Corporate		GEO AISC			Yaramoko		GEO AISC
Cash cost applicable per gold equivalent ounce sold		76,216			77,234		38,418		–		191,868			39,960		231,828
Inventory net realizable value adjustment		–			–		–		–		–			–		–
Royalties and taxes		270			33,439		822		–		34,531			8,830		43,361
Worker’s participation		–			–		2,276		–		2,276			–		2,276
General and administration		7,937			8,255		4,957		46,712		67,861			1,602		69,463
Total cash costs		84,423			118,928		46,473		46,712		296,536			50,392		346,928
Sustaining capital1		33,523			60,426		8,578		–		102,527			2,813		105,340
Blue chips gains (investing activities)1		(1,319	)		–		–		–		(1,319	)		–		(1,319	)
All-in sustaining costs		116,627			179,354		55,051		46,712		397,744			53,205		450,949
Gold equivalent ounces sold		67,087			115,386		27,315		–		209,788			37,734		247,522
All-in sustaining costs per ounce		1,738			1,554		2,015		–		1,896			1,410		1,822
Gold equivalent was calculated using the realized prices for gold of $3,231/oz Au, $34.9/oz Ag, $1,960/t Pb and $2,768/t Zn for Year to Date 2025
Figures may not add due to rounding
1 Presented on a cash basis

		Continuing Operations												Discontinued Ops				Total
AISC Per Gold Equivalent Ounce Sold – Year to Date 2024		Lindero			Séguéla		Caylloma		Corporate		GEO AISC			Yaramoko		San Jose		GEO AISC
Cash cost applicable per gold equivalent ounce sold		72,664			56,651		45,374		–		174,689			75,890		72,761		323,340
Inventory net realizable value adjustment		–			–		–		–		–			1,777		–		1,777
Royalties and taxes		458			17,244		949		–		18,651			15,782		2,210		36,643
Worker’s participation		–			–		1,361		–		1,361			–		–		1,361
General and administration		9,095			6,716		3,871		29,262		48,944			1,282		4,850		55,076
Total cash costs		82,217			80,611		51,555		29,262		243,645			94,731		79,821		418,197
Sustaining capital1		48,407			28,134		15,559		–		92,100			24,724		675		117,499
Blue chips gains (investing activities)1		(8,311	)		–		–		–		(8,311	)		–		–		(8,311	)
All-in sustaining costs		122,313			108,745		67,114		29,262		327,434			119,455		80,496		527,385
Gold equivalent ounces sold		69,430			101,369		39,399		–		210,198			86,621		34,218		331,037
All-in sustaining costs per ounce		1,762			1,073		1,703		–		1,558			1,379		2,352		1,593
Gold equivalent was calculated using the realized prices for gold of $2,307/oz Au, $27.1/oz Ag, $2,091/t Pb, and $2,692/t Zn for Year to Date 2024.
Figures may not add due to rounding
1 Presented on a cash basis

Reconciliation of cost of sales to cash cost per payable ounce of silver equivalent sold for the three months ended June 30, 2025 and for the three and nine months ended September 30, 2025 and 2024

Cash Cost Per Silver Equivalent Ounce Sold – Q2 2025		Caylloma
Cost of sales		17,793
Depletion, depreciation, and amortization		(4,268	)
Royalties and taxes		(295	)
Other		(663	)
Treatment and refining charges		28
Cash cost applicable per silver equivalent sold		12,595
Ounces of silver equivalent sold1		830,824
Cash cost per ounce of silver equivalent sold ($/oz)		15.16
1 Silver equivalent sold is calculated using a silver to lead ratio of 1:35.5 pounds, and silver to zinc ratio of 1:24.7 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
Figures may not add due to rounding

Cash Cost Per Silver Equivalent Ounce Sold – Q3 2025		Caylloma
Cost of sales		19,317
Depletion, depreciation, and amortization		(5,199	)
Royalties and taxes		(287	)
Other		(668	)
Treatment and refining charges		416
Cash cost applicable per silver equivalent sold		13,579
Ounces of silver equivalent sold1,2		757,797
Cash cost per ounce of silver equivalent sold ($/oz)		17.92
1 Silver equivalent sold is calculated using a silver to gold ratio of 85.1:1, silver to lead ratio of 1:44.2 pounds, and silver to zinc ratio of 1:30.8 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
Figures may not add due to rounding

Cash Cost Per Silver Equivalent Ounce Sold – Q3 2024		Caylloma
Cost of sales		19,820
Depletion, depreciation, and amortization		(4,465	)
Royalties and taxes		(366	)
Other		(279	)
Treatment and refining charges		2,249
Cash cost applicable per silver equivalent sold		16,959
Ounces of silver equivalent sold1,2		1,139,823
Cash cost per ounce of silver equivalent sold ($/oz)		14.88
1 Silver equivalent sold is calculated using a silver to gold ratio of 85.9:1, silver to lead ratio of 1:31.6 pounds, and silver to zinc ratio of 1:23.2 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
Figures have been restated to remove Right of Use
Figures may not add due to rounding

Cash Cost Per Silver Equivalent Ounce Sold – Year to Date 2025		Caylloma
Cost of sales		54,573
Depletion, depreciation, and amortization		(13,836	)
Royalties and taxes		(822	)
Other		(1,991	)
Treatment and refining charges		494
Cash cost applicable per silver equivalent sold		38,418
Ounces of silver equivalent sold1,2		2,529,394
Cash cost per ounce of silver equivalent sold ($/oz)		15.19
1 Silver equivalent sold is calculated using a silver to gold ratio of 95.9:1, silver to lead ratio of 1:39.3 pounds, and silver to zinc ratio of 1:27.8 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
Figures may not add due to rounding

Cash Cost Per Silver Equivalent Ounce Sold – Year to Date 2024		Caylloma
Cost of sales		53,164
Depletion, depreciation, and amortization		(11,647	)
Royalties and taxes		(949	)
Other		(960	)
Treatment and refining charges		5,766
Cash cost applicable per silver equivalent sold		45,374
Ounces of silver equivalent sold1,2		3,372,741
Cash cost per ounce of silver equivalent sold ($/oz)		13.45
1 Silver equivalent sold is calculated using a silver to gold ratio of 82.8:1, silver to lead ratio of 1:28.4 pounds, and silver to zinc ratio of 1:22.1 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
Figures have been restated to remove Right of Use
Figures may not add due to rounding

Reconciliation of all-in sustaining cash cost and all-in cash cost per payable ounce of silver equivalent sold for the three months ended June 30, 2025 and for the three and nine months ended September 30, 2025 and 2024

AISC Per Silver Equivalent Ounce Sold – Q2 2025		Caylloma
Cash cost applicable per silver equivalent ounce sold		12,595
Royalties and taxes		295
Worker’s participation		760
General and administration		1,672
Total cash costs		15,322
Sustaining capital3		2,729
All-in sustaining costs		18,051
Silver equivalent ounces sold1		830,824
All-in sustaining costs per ounce2		21.73
1 Silver equivalent sold is calculated using a silver to lead ratio of 1:35.5 pounds, and silver to zinc ratio of 1:24.7 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
3 Presented on a cash basis

AISC Per Silver Equivalent Ounce Sold – Q3 2025		Caylloma
Cash cost applicable per silver equivalent ounce sold		13,579
Royalties and taxes		287
Worker’s participation		777
General and administration		830
Total cash costs		15,473
Sustaining capital3		3,604
All-in sustaining costs		19,077
Silver equivalent ounces sold1,2		757,797
All-in sustaining costs per ounce		25.17
1 Silver equivalent sold is calculated using a silver to gold ratio of 85.1:1, silver to lead ratio of 1:44.2 pounds, and silver to zinc ratio of 1:30.8 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
3 Presented on a cash basis

AISC Per Silver Equivalent Ounce Sold – Q3 2024		Caylloma
Cash cost applicable per silver equivalent ounce sold		16,959
Royalties and taxes		366
Worker’s participation		472
General and administration		1,246
Total cash costs		19,043
Sustaining capital3		6,817
All-in sustaining costs		25,860
Silver equivalent ounces sold1,2		1,139,823
All-in sustaining costs per ounce		22.69
1 Silver equivalent sold is calculated using a silver to gold ratio of 85.9:1, silver to lead ratio of 1:31.6 pounds, and silver to zinc ratio of 1:23.2 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
3 Presented on a cash basis

AISC Per Silver Equivalent Ounce Sold – Year to Date 2025		Caylloma
Cash cost applicable per silver equivalent ounce sold		38,418
Royalties and taxes		822
Worker’s participation		2,276
General and administration		4,957
Total cash costs		46,473
Sustaining capital3		8,578
All-in sustaining costs		55,051
Silver equivalent ounces sold1,2		2,529,394
All-in sustaining costs per ounce		21.76
1 Silver equivalent sold is calculated using a silver to gold ratio of 95.9:1, silver to lead ratio of 1:39.3 pounds, and silver to zinc ratio of 1:27.8 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
3 Presented on a cash basis

AISC Per Silver Equivalent Ounce Sold – Year to Date 2024		Caylloma
Cash cost applicable per silver equivalent ounce sold		45,374
Royalties and taxes		949
Worker’s participation		1,361
General and administration		3,871
Total cash costs		51,555
Sustaining capital3		15,559
All-in sustaining costs		67,114
Silver equivalent ounces sold1,2		3,372,741
All-in sustaining costs per ounce		19.90
1 Silver equivalent sold is calculated using a silver to gold ratio of 82.8:1, silver to lead ratio of 1:28.4 pounds, and silver to zinc ratio of 1:22.1 pounds.
2 Silver equivalent is calculated using the realized prices for gold, silver, lead, and zinc. Refer to Financial Results – Sales and Realized Prices
3 Presented on a cash basis

Additional information regarding the Company’s financial results and ongoing activities is available in the unaudited condensed interim financial statements for the three and nine months ended September 30, 2025 and 2024 and accompanying Q3 2025 MD&A. These documents can be accessed on Fortuna’s website at www.fortunamining.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov/edgarwww.sec.gov/edgar.

Conference Call and Webcast
A conference call to discuss the financial and operational results will be held on Thursday, November 6, 2025, at 9:00 a.m. Pacific time | 12:00 p.m. Eastern time. Hosting the call will be Jorge A. Ganoza, President and CEO, Luis D. Ganoza, Chief Financial Officer, Cesar Velasco, Chief Operating Officer – Latin America, and David Whittle, Chief Operating Officer – West Africa.

Shareholders, analysts, media and interested investors are invited to listen to the live conference call by logging onto the webcast at: https://www.webcaster5.com/Webcast/Page/1696/53144 or over the phone by dialing in just prior to the starting time.

Conference call details:

Date: Thursday, November 6, 2025
Time: 9:00 a.m. Pacific time | 12:00 p.m. Eastern time

Dial in number (Toll Free): +1.888.506.0062
Dial in number (International): +1.973.528.0011
Access code: 360013

Replay number (Toll Free): +1.877.481.4010
Replay number (International): +1.919.882.2331
Replay passcode: 53144

Playback of the earnings call will be available until Thursday, November 20, 2025. Playback of the webcast will be available until Friday, November 6, 2026. In addition, a transcript of the call will be archived on the Company’s website.

About Fortuna Mining Corp.

Fortuna Mining Corp. is a Canadian precious metals mining company with three operating mines and a portfolio of exploration projects in Argentina, Côte d’Ivoire, Mexico, and Peru, as well as the Diamba Sud Gold Project in Senegal. Sustainability is at the core of our operations and stakeholder relationships. We produce gold and silver while creating long-term shared value through efficient production, environmental stewardship, and social responsibility. For more information, please visit our website at www.fortunamining.com

ON BEHALF OF THE BOARD

Jorge A. Ganoza

President, CEO, and Director
Fortuna Mining Corp.

Investor Relations:

Carlos Baca | [email protected] | fortunamining.com | X| LinkedIn|YouTube

Forward-looking Statements

This news release contains forward-looking statements which constitute “forward-looking information” within the meaning of applicable Canadian securities legislation and “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 (collectively, “Forward-looking Statements”). All statements included herein, other than statements of historical fact, are Forward-looking Statements and are subject to a variety of known and unknown risks and uncertainties which could cause actual events or results to differ materially from those reflected in the Forward-looking Statements. The Forward-looking Statements in this news release include, without limitation, statements about the Company’s plans for its mines and mineral properties, the Company’s expectations regarding meeting annual production guidance and annual AISC guidance; and the estimated annual production guidance for the Séguéla Mine in 2026; the timing for the repair of the primary crusher at the Lindero Mine and that the measures that the Company has put in place to mitigate the risks related to same will be successful and will not have a material impact on the mine’s production guidance for the year; statements relating to the preliminary economic assessment for the Diamba Sud Gold Project, including the development of an open pit mine; the projected economics for the Project, including the net present value of the Project, the internal rate of return on the Project and the Project payback period; advancing the Diamba Sud Gold Project towards a definitive feasibility study and a construction decision in the first half of 2026; the Company’s business strategy, plans and outlook; the merit of the Company’s mines and mineral properties; mineral resource and reserve estimates, metal recovery rates, concentrate grade and quality; changes in tax rates and tax laws, requirements for permits, anticipated approvals and other matters. Often, but not always, these Forward-looking Statements can be identified by the use of words such as “estimated”, “expected”, “anticipated”, “potential”, “open”, “future”, “assumed”, “projected”, “used”, “detailed”, “has been”, “gain”, “planned”, “reflecting”, “will”, “containing”, “remaining”, “to be”, or statements that events, “could” or “should” occur or be achieved and similar expressions, including negative variations.

The forward-looking statements in this news release also include financial outlooks and other forward-looking metrics relating to the Company and its business, including references to financial and business prospects and future results of operations, including production, and cost guidance and anticipated future financial performance. Such information, which may be considered future oriented financial information or financial outlooks within the meaning of applicable Canadian securities legislation (collectively, “

FOFI

”), has been approved by management of the Company and is based on assumptions which management believes were reasonable on the date such FOFI was prepared, having regard to the industry, business, financial conditions, plans and prospects of the Company and its business and properties. These projections are provided to describe the prospective performance of the Company’s business. Nevertheless, readers are cautioned that such information is highly subjective and should not be relied on as necessarily indicative of future results and that actual results may differ significantly from such projections. FOFI constitutes forward-looking statements and is subject to the same assumptions, uncertainties, risk factors and qualifications as set forth below.

Forward-looking Statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any results, performance or achievements expressed or implied by the Forward-looking Statements. Such uncertainties and factors include, among others, changes in general economic conditions and financial markets
;
risks associated with war or other geo-political hostilities, such as the Ukrainian – Russian and the Israel – Hamas conflicts, any of which could continue to cause a disruption in global economic activity; fluctuation in currencies and foreign exchange rates; increases in the rate of inflation; the imposition or any extension of capital controls in countries in which the Company operates; any changes in tax laws in Argentina and the other countries in which we operate; changes in the prices of key supplies; uncertainty relating to nature and climate change conditions; risks associated with climate change legislation; laws and regulations regarding the protection of the environment (including greenhouse gas emission reduction and other decarbonization requirements and the uncertainty surrounding the interpretation of omnibus Bill C-59 and the related amendments to the Competition Act (Canada); our ability to manage physical and transition risks related to climate change and successfully adapt our business strategy to a low carbon global economy; technological and operational hazards in Fortuna’s mining and mine development activities; risks related to water and power availability; risks inherent in mineral exploration; uncertainties inherent in the estimation of mineral reserves, mineral resources, and metal recoveries; changes to current estimates of mineral reserves and resources; changes to production and cost estimates; changes in the position of regulatory authorities with respect to the granting of approvals or permits; governmental and other approvals; changes in government, political unrest or instability in countries where Fortuna is active; labor relations issues; as well as those factors discussed under “Risk Factors” in the Company’s Annual Information Form for the financial year ended December 31, 2024 filed with the Canadian Securities Administrators and available at

www.sedarplus.ca

and filed with the U.S. Securities and Exchange Commission as part of the Company’s Form 40-F and available at www.sec.gov/edgar. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in Forward-looking Statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended.

Forward-looking Statements contained herein are based on the assumptions, beliefs, expectations and opinions of management, including, but not limited to, the accuracy of the Company’s current mineral resource and reserve estimates; that the Company’s activities will be conducted in accordance with the Company’s public statements and stated goals; that there will be no material adverse change affecting the Company, its properties or changes to production estimates (which assume accuracy of projected ore grade, mining rates, recovery timing, and recovery rate estimates and may be impacted by unscheduled maintenance, labor and contractor availability and other operating or technical difficulties); geo-political uncertainties that may affect the Company’s production, workforce, business, operations and financial condition; the expected trends in mineral prices and currency exchange rates; that the Company will be successful in mitigating the impact of inflation on its business and operations; that all required approvals and permits will be obtained for the Company’s business and operations on acceptable terms; that there will be no significant disruptions affecting the Company’s operations, the ability to meet current and future obligations and such other assumptions as set out herein. Forward-looking Statements are made as of the date hereof and the Company disclaims any obligation to update any Forward-looking Statements, whether as a result of new information, future events or results or otherwise, except as required by law. There can be no assurance that these Forward-looking Statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, investors should not place undue reliance on Forward-looking Statements. 

Cautionary Note to United States Investors Concerning Estimates of Reserves and Resources 
 

Reserve and resource estimates included in this news release have been prepared in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects (“NI 43-101”) and the Canadian Institute of Mining, Metallurgy, and Petroleum Definition Standards on Mineral Resources and Mineral Reserves. NI 43-101 is a rule developed by the Canadian Securities Administrators that establishes standards for public disclosure by a Canadian company of scientific and technical information concerning mineral projects. Unless otherwise indicated, all mineral reserve and mineral resource estimates contained in the technical disclosure have been prepared in accordance with NI 43-101 and the Canadian Institute of Mining, Metallurgy and Petroleum Definition Standards on Mineral Resources and Reserves. Canadian standards, including NI 43-101, differ significantly from the requirements of the Securities and Exchange Commission, and mineral reserve and resource information included in this news release may not be comparable to similar information disclosed by U.S. companies. 

PEA Key Highlights

The following table summarizes the key assumptions, operational parameters, economic results, and AISC values from the PEA.

Metrics	Units	Results
Gold price	$/oz	2,750
Life of mine	year	8.1
Total mineralized material mined1	Mt	17.75
Contained gold in mineralized material mined1	koz	932
Strip ratio	Waste:mineralized material	5.5:1
Throughput initial 3 years (primarily oxide)	Mtpa	2.5
Throughput after 3 years (primarily fresh)	Mtpa	2.0
Head grade	g/t Au	1.63
Recoveries	%	90	%
Gold production
Total Production over LOM	koz	840
Average annual production, LOM	koz	106
Average annual production, first 3 years	koz	147
Per unit costs over LOM
Total mining costs	$/t, mined	$4.82
Processing	$/t, processed	$13.91
G&A	$/t, processed	$6.70
Cash costs 1
Average operating cash costs2, LOM	$/oz	$1,081
Average operating cash costs2, first 3 years	$/oz	$759
AISC 1
Average AISC2, LOM	$/oz	$1,238
Average AISC2, first 3 years	$/oz	$904
Capital costs
Initial capital expenditure	$ M	$283
Sustaining capital, operations + Infrastructure(includes closure costs)	$ M	$48
NPV 5% , pre-tax (100% project basis)	$M	$ 772
Pre-tax IRR	%	86	%
NPV 5% , after-tax (100% project basis)	$M	$ 563
After-tax IRR	%	72	%
Payback period	year	0.8
Annual EBITDA 2
Average EBITDA2over LOM	$ M	$167
Average EBITDA2over first 3 years	$ M	$277

Notes:
1.		The pit optimization shells used for the mining inventory were generated using a gold price of $2,300 per ounce.
2.		This is a non-IFRS financial measure. The definition and purpose of this non-IFRS financial measure is included in the Q3 2025 MD&A under the heading “Non-IFRS Measures. Non-IFRS financial measures have no standardized meaning under IFRS and therefore, may not be comparable to similar measures presented by other issuers.
3.		Average operating cash costs and average AISC represent costs for projected production for the LOM at the time of gold sales.
4.		The PEA is presented on a 100 percent project basis. However, upon the granting of the exploitation permit, the Senegalese Government will be entitled to a 10 percent free-carried interest in the Project, with the right for the State to acquire an additional contributory interest of up to 25 percent.
5.		The economic analysis was carried out using a discounted cash flow approach on a pre-tax and after-tax basis, based on the gold price of $2,750/oz.
6.		The IRR on total investment that is presented in the economic analysis was calculated assuming a 100% ownership in Diamba Sud.
7.		The NPV was calculated from the after-tax cash flow generated by the Project, based on a discounted rate of 5% and an effective date of October 10, 2025.
8.		The PEA assumes that the percentage of certain royalties and taxes payable to the State, the percentage of the investment tax credit available to the company and the percentage payable to the social development fund will be in accordance with the provisions of the Mining Convention between Boya S.A. and the State of Senegal dated April 8, 2015. There can be no assurance that such provisions will not be renegotiated by the State as part of the exploitation permit approval process.
9.		The PEA is preliminary in nature, and it includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves, and, as such, there is no certainty that the PEA results will be realized. Mineral resources that are not mineral reserves do not have demonstrated economic viability.

Further information regarding the PEA referenced in this news release, including details on data verification, key assumptions, parameters, opportunities, risks, and other factors, will be contained in a technical report prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects and filed on SEDAR+ at www.sedarplus.com and on EDGAR at www.sec.gov/edgar under the Company’s profile by November 28, 2025.

PDF available: http://ml.globenewswire.com/Resource/Download/d3fea458-4875-487c-b5d6-a95a8d6d694d